All News
Ixekizumab Superior to Etanercept in Psoriasis
The UNCOVER-2 and UNCOVER-3 trials were presented at the American Academy of Dermatology (AAD) Annual Meeting taking this week in Washington, D.C.
Read Article
Subclinical Synovitis in Psoriasis Portends Future Psoriatic Arthritis
It is estimated that nearly 30% of psoriasis patients will develop psoriatic arthritis (PsA). This prevalence was studied by performing MRI scans on asymptomatic psoriasis (n=56) and 30 control patients without arthritis.
Read Article
Challenges of Dermatomyositis Progress
In the current issue of Lancet, Pierre Miossec discusses the challenges of studying and managing juvenile dermatomyositis and, specifically, the
Read Article
Rheumatoid Arthritis, TNF inhibitors and the Risk of Skin Cancer
Rheumatoid arthritis (RA) patients are said to have a neutral risk for neoplasia, but this is because they have a lower risk of colon cancer and breast cancer but a higher risk of lung cancer, lymphoma and skin cancers.
Read Article
Secukinumab Shows Efficacy in Two Ankylosing Spondylitis Trials
NEJM has published the results of two studies wherein IL-17 inhibition with secukinumab (SEC) was shown to be effective in patients with anklylosing spondylitis.
Read Article
Tofacitinib Shows Promise in Alopecia, Eczema and Vitiligo
Tofacitinib has been approved for use in rheumatoid arthritis.
Read ArticleJuvenile Dermatomyositis Responds Best to Methotrexate and Prednisone
Lancet reports the results of a randomized controlled trial comparing prednisone alone to prednisone combined with either methotrexate (MTX) or cyclosporine (CyA) in new-onset juvenile dermatomyositis (JDM).
Read Article
The Rising Price of Dermatologic Drugs
Containment of health care costs was a primary goal of the Patient Protection and Affordable Care Act. But there is little evidence of success in curbing the rising price of prescription drugs. As such, many medications are unaffordable to those who need them.
Read Article
Chronic Digital Ulcers in Systemic Sclerosis Portends More Complications
A prospective, international observational study of systemic sclerosis patients enrolled in the Digital Ulcers Outcome (DUO) Registry: Patients were required to have ≥3 follow-up visits over at least a 2 year observation period between 2008-2013.
Read Article
Eczema May Respond to Tofacitinib
A recent report from the Journal of the American Academy of Dermatology found that the oral Janus kinase (JAK) inhibitor tofacitinib to be effective in the treatment of moderate to severe atopic dermatitis.
Read Article
From Psoriasis to PsA: Who and Why?
The number of patients with psoriasis who go on to develop psoriatic arthritis (PsA) is considerably higher than has previously been estimated, a prospective cohort study found.
Read Article
Repeat Skin Cancer Risk with Methotrexate and Biologics
Using Medicare claims data, a retrospective cohort study analyzed the risk of a second non-melanomatous skin cancer (NMSC) in 9460 individuals (6841 with RA and 2788 with IBD).
Read Article
High Level Skin Responses Seen with Inhibitor of IL-23p19 in Psoriasis
Rheumatology News reports the results of a novel trial presented at the European Academy of Dermatology and Venereology meeting in Copenhagen.
Read Article
Brodalumab vs. Ustekinumab: Head-to-Head Studies of Psoriasis
AMAGINE-2 and AMAGINE-3 are in two phase 3 studies that compare multiple doses of brodalumab (anti-IL-17) and ustekinumab (anti-12/23) in adults with moderate-to-severe psoriasis.
Read Article
Ustekinumab Effective in Adolescents with Psoriasis
Biologic and new drug development seldom targets children and adolescents. This study evaluated the efficacy and safety of ustekinumab in adolescents age 12 to 17 years with moderate-to-severe psoriasis,
Read Article
TICOPA Study: Tight Control in Psoriatic Arthritis
Tight control in rheumatoid arthritis was introduced with the TICORA trial and validated in numerous treat-to-target studies since. Now the benefits of tight control in psoriatic arthritis (PsA) have been reported.
Read Article
Adalimumab FDA Approved for Hidradenitis Suppurativa
Abbvie announced on 9/10/15 that adalimumab (Humira) has been FDA approved for the treatment of moderate to severe hidradenitis suppurativa (HS) and is now the first and only FDA-approved therapy for adults with HS.
Read Article
VEGF121-Fibrin as a Potential Therapy for Skin Ulcers in Systemic Sclerosis
The etiology of systemic sclerosis (SSc) remains unclear, but appears to involve complex pathogenic interactions between the immune system, the vasculature and fibrotic processes.
Read Article
Secukinumab Bests Ustekinumab in Psoriasis CLEAR Study
The CLEAR study was a one-year, randomized, double-blind trial compared subcutaneous standard doses of secukinumab (anti-IL17) and ustekinumab (anti-IL12/23) in patients with moderate-severe plaque psoriasis.
Read Article
Priorities for NIAMS Research Funding
Dr. Steven Katz describes how NIAMS sets priorities for investing congressionally-appropriated funds.
Read Article
